Bringing together international experts with the latest technologies and pioneering research, Montefiore Einstein Center for Cancer Care, in collaboration with the National Cancer Institute-designated Albert Einstein Cancer Center, advances the front lines of prevention, diagnosis and treatment of rare and common cancers. With leadership provided by Steven K. Libutti, MD, Montefiore Einstein Center for Cancer Care offers a multi-disciplinary approach to care, integrating science and medicine to deliver the most current treatments available for both common and rare types of cancer at all stages.
The physicians listed below are among the cancer experts from the Center who will be on-site at the 2012 American Society of Clinical Oncology (ASCO) meeting June 1-5 in Chicago. These doctors will be available to discuss research they are presenting, and to provide external commentary on other noteworthy studies involving lung cancer, breast cancer, melanoma, lymphoma, head and neck and other cancer types that will be highlighted at ASCO.
Roman Perez-Soler, MD, Chairman, Department of Oncology
•Areas of expertise include lung cancer, inhalation therapy, experimental cancer therapies
Dr. Perez-Soler will present results of a study of cutaneous toxicity secondary to erlotinib therapy in patients with non-small cell lung cancer: https://abstract.asco.org/AbstView_114_98904.html
Contact information: 646-209-5116 (cell), [email protected]
Joseph Sparano, MD, Associate Chairman of Oncology
•Areas of expertise include breast cancer, lymphoma, HIV- associated cancer, obesity's link to cancer, phase I-III clinical trials, clinical application of genomic profiling
Dr. Sparano will chair the breast cancer session on 6/5 and is a co-author of a study on DCIS score at that session: https://abstract.asco.org/AbstView_114_98808.html
Dr. Sparano is also a co-author of a study of neurocognitive function on the Tailorx trial:
https://abstract.asco.org/AbstView_114_99178.html
Contact information: 917-751-5346 (cell), [email protected]
Stefan K. Barta, MD, MS, Medical Oncology
•Areas of expertise include HIV-associated lymphomas, acute and chronic leukemias, multiple myeloma
Dr. Barta will give an oral presentation at the lymphoma session on 6/2 about the largest study to date of treatment for HIV-positive patients with lymphoma, the most common malignancy in this patient population: https://abstract.asco.org/AbstView_114_94501.html
Contact information: 917-912-8112 (cell), [email protected]
Bilal Piperdi, MD, Director, Lung Cancer Program
•Areas of expertise include lung cancer, targeted therapies
Dr. Piperdi will co-chair the 6/3 poster discussion on Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers
Contact information: [email protected]
Madhur Garg, MD, Radiation Oncology
•Areas of expertise include IMRT and IGRT, stereotactic radiosurgery for brain and spinal cord tumors, stereotactic body radiation therapy (SBRT) for lung and liver malignancies; functional imaging and adaptive planning for head/neck malignancies
Dr. Garg is the national principal investigator of a Phase II study of Cetuximab plus Cisplatin, 5FU and Radiation in Immunocompetent and HIV-positive Patients with Squamous Cell Carcinoma of the Anal Canal, and will present study results on 6/4: https://abstract.asco.org/AbstView_114_101205.html
Contact information: 718-644-4895 (cell), [email protected]
Sanjay Goel, MD, Medical Oncology
•Areas of expertise include cancer drug development and phase I oncology clinical trials
Dr. Goel will present a poster on a phase I study of elisidepsin and erlotinib in patients with advanced solid tumors: https://abstract.asco.org/AbstView_114_96241.html
He has also been selected for the 2012-2013 class of the ASCO Leadership Development Program, a year-long educational series for future leaders in both ASCO and the practice of oncology.
Contact information: 646-685-9242 (cell), [email protected]
Petra Rietschel, MD, PhD, Director, Melanoma/Sarcoma Program
•Areas of expertise include melanoma, sarcoma, breast cancer
Dr. Rietschel is a co-author of a poster on a phase II multicenter study of the IGF-1 receptor antibody cixutumumab and the mTOR inhibitor temsirolimus in patients with refractory IGF-1R positive and negative bone and soft tissue sarcomas: https://abstract.asco.org/AbstView_114_92229.html
She is also a melanoma expert who can comment on updates of therapies including ipilimumab and B-RAF inhibitors.
Contact information: 646-823-4912 (cell), [email protected]
Missak Haigentz, MD, Medical Oncology
•Areas of expertise include head and neck cancer, HIV and cancer
Dr. Haigentz is a co-author of a study analyzing quality of life in patients undergoing concurrent chemotherapy and radiation therapy for locally advanced head and neck cancer: https://abstract.asco.org/AbstView_114_100299.html
Contact information: [email protected]
Innovative urine test could improve pancreatic cancer survival rates